Rituximab for children with immune thrombocytopenia: A systematic review

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Liang, Yi ^a,b   Zhang, Lingli ^a   Gao, Ju ^a   Hu, Die ^a,b   Ai, Yuan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; MONOCLONAL ANTIBODY;

ANGIONEUROTIC EDEMA; APHASIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CHICKENPOX; CHILD CARE; CHILL; CLINICAL ASSESSMENT; COGNITION; COMMON VARIABLE IMMUNODEFICIENCY; COUGHING; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENTEROVIRUS INFECTION; FACE EDEMA; FATIGUE; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION SENSITIVITY; MENINGOENCEPHALITIS; MUSCLE CRAMP; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCEPTION DEAFNESS; PNEUMONIA; PRURITUS; RELAPSE; RESPIRATORY TRACT DISEASE; SERUM SICKNESS; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THROAT TIGHTNESS; THROMBOCYTE COUNT; VIRUS INFECTION; VOMITING; WHITE MATTER; BLOOD; CHILD; DRUG ADMINISTRATION; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHILD; DRUG ADMINISTRATION SCHEDULE; HUMANS; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

EID: 84861616693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036698     Document Type: Article

References (49)

1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, et al. (2009) Standardization of terminology, definitions and outcome criteria in an international working group immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113: 2386-2393.
2. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, et al. (2010) The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85: 174-180.
3. Kühne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, et al. (2003) A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 143: 605-608.
4. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, et al. (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115: 168-186.
5. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, et al. (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171: 1581-1587.
6. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, et al. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95: 3900-3908.
7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242.
8. Eupropean Medicine Agency website. Summary of European public assessment report for Mabthera. 20 Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000165/human_med_000897.jsp&mid=WC0b01ac058001d124. Accessed 2012 Jan.
9. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, et al. (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146: 25-33.
10. Cooper N, Bussel JB, (2010) The long-term impact of rituximab for childhood immune thrombocytopenia. Curr Rheumatol Rep 12: 94-100.
11. National Institute for Health and Clinical Excellence (NICE) website. Quality assessment for case series. 11 Available: http://www.nice.org.uk/nicemedia/pdf/Appendix_04_qualityofcase_series_form_preop.pdf. Accessed 2011 Apr.
12. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
13. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1011.
14. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
15. Landis JR, Koch GG, (1997) The measurement of observer agreement for categorical data. Biometrics 33: 159-174.
16. Taube T, Schmid H, Reinhard H, von Stackelberg A, Overberg US, (2005) Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 90: 281-283.
17. Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, et al. (2005) Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 146: 217-221.
18. Bennet CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, et al. (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107: 2639-2642.
19. Bader-Meunier B, Aladjidi N, Bellmann F, Monpoux F, Nelken B, et al. (2007) Rituximab therapy for childhood Evans syndrome. Haematologica 92: 1691-1694.
20. Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, et al. (2008) Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 50: 822-825.
21. Dogan M, Oner AF, Acikgoz M, Uner A, (2009) Treatment of chronic immune thrombocytopenic purpura with rituximab in children. Indian J Pediatr 76: 1141-1144.
22. Kumar S, Benseler SM, Kirby-Allen M, Silverman ED, (2009) B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 123: e159-63.
23. Parodi E, Rivetti E, Amendola G, Bisogno G, Calabrese R, et al. (2008) Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol 144: 552-558.
24. Rao VK, Price S, Perkins K, Aldridge P, Tretler J, et al. (2009) Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferativesyndrome (ALPS). Pediatr Blood Cancer 52: 847-852.
25. Citak EC, Citak FE, (2011) Treatment results of children with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. J Trop Pediatr 57: 71-72.
26. Xu S, Bai H, Wang C, Zhang Q, Xi R, et al. (2011) The effect of rituximab in chronic refractory immune thrombocytopenic purpura in children. J China Pediatr Blood Cancer 16: 129-131.
27. Yang J, Wang X, Wang H, Li XQ, (2011) Low dose of rituximab for children with chronic immune thrombocytopenia and a review of the literatures. Chinese Journal of Obstetrics & Gynecology and Pediatrics 7: 474-475.
28. Grace RF, Bennett CM, Ritchey AK, Jeng M, Thornburg CD, et al. (2011) Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer Jun 14 [Epub ahead of print].
29. Sharma A, Nair V, Mishra DK, Kotwal J, Chopra GS, et al. (2005) Chimeric anti CD-20 monoclonal antibody-rituximab in refractory childhood idiopathic thrombocytopenic purpura: an Indian experience. [Abstract] Blood 106: 4010.
30. Kim JY, Lee, KS, Kang HJ, Kook H, Koo HH, et al. (2009) Rituximab treatment in childhood chronic immune thrombocytopenic purpura (ITP). [Abstract] Blood 114: 4461.
31. Pospisilova D, Smisek P, Su kova M, Votava T, Hak J, et al. (2010) Experience with rituximab treatment in children with severe refractory immune thrombocytopenic purpura in the Czech Republic. Ann Hematol 89 (Suppl 1): S105-S109.
32. Sampaio I, Palaré MJ, Ferrão A, Morais A, (2010) Saianda A. Rrituximab in the treatment of immune thrombocytopenia: follow-up in seven cases. Haematologica: 95: 750.
33. Wang H-M, Sui T, Yang Y, Zhou Z, Liu X, et al. (2011) Low-dose rituximab treatment in Chinese patients with immune thrombocytopenia. J Pediatr 146: 330.
34. Lorenzana AN, Mularoni PJ, Doyle M, Greenwood R, Sawaf H, (2002) Therapeutic effect of rituximab (Rituxan) in childhood immune thrombocytopenia and Evan's syndrome. [Absract] 1043.
35. Bengtson KL, Skinner MA, Ware RE, (2003) Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. J Pediatr 143: 670-673.
36. Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, et al. (2003) Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis: 36: e47-49.
37. Pusiol A, Cesaro S, Nocerino A, Picco G, Zanesco L, (2004) Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia. Eur J Pediatr 163: 305-307.
38. Yadav SP, Misra R, Gaurav K, Sachdeva A, (2006) Rituximab use in children - a single center experience. [Absract] Blood 108: 3892.
39. Bisogno G, (2007) Persistent B-cell depletion after rituximab for thrombocytopenic purpura. Eur J Pediatr 166: 85-86.
40. Kim JJ, Thrasher AJ, Jones AM, Davies EG, Cale CM, (2007) Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency. Br J Haematol 138: 94-96.
41. Gentner J, Morra M, Knutsen AP, (2008) Development of common variable immunodeficiency in an 8-year-old boy treated with rituximab for idiopathic thrombocytopenia. Pediatr Asthma Allergy Immunol 21: 99-104.
42. Adeli MM, Eichner BH, Thornburg C, Williams L, (2009) Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. Pediatr Hematol Oncol 26: 566-572.
43. Cooper N, Davies EG, Thrasher A, (2009) Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinemia requiring replacement intravenous immunoglobulin. British Journal of Haematology 146: 120-122.
44. Goto S, Goto H, Tanoshima R, Kato H, Takahashi H, et al. (2009) Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 89: 305-309.
45. Romanos-Sirakis E, Feigenbaum BA, (2011) Immediate hypersensitivity reaction and successful rapid desensitization to rituximab followed by serum sickness in a 4 year old. Journal of Allergy and Clinical Immunology 127: AB198.
46. National Institute of Health website. National Cancer Institute common terminology criteria for adverse events, Version 4.0. 25 Available: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 2011 Apr.
47. Pescovitz MD, (2006) Rituximab, an Anti-CD20 Monoclonal antibody: history and mechanism of action. Am. J. Transplant 6: 859-866.
48. Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME, (2007) Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 109: 2182-2189.
49. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, et al. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840.